Improving the Efficacy of Reduced Intensity Allogeneic Transplantation for Lymphoma using Radioimmunotherapy

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 7, 2006, Pages 697-702

  Gopal, Ajay K ^a,c   Pagel, John M ^a,c   Rajendran, Joseph G ^b   Maloney, David G ^a,c   Appelbaum, Frederick R ^a,c   Sorror, Mohamed L ^c   Sandmaier, Brenda M ^a,c   Storb, Rainer ^a,c   Press, Oliver W ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Allogeneic; CD20; Lymphoma; Non myleloablative; Radioimmunotherapy

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER REGRESSION; CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHODGKIN LYMPHOMA; RADIOIMMUNOTHERAPY; REVIEW; RISK ASSESSMENT; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MICE; RADIOIMMUNOTHERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33745116946     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.03.014     Document Type: Review

References (34)

1. van Besien K., Loberiza Jr. F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 (2003) 3521-3529
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
3. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma. low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 (2001) 3595-3599
4. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004) 3535-3542
5. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 3819-3829
6. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104 (2004) 3865-3871
7. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22 (2004) 2172-2176
8. Dean R.M., Fowler D.H., Wilson W.H., et al. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11 (2005) 593-599
9. van Besien K., Sobocinski K.A., Rowlings P.A., et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92 (1998) 1832-1836
10. Golden J., Gooley T., Gopal A., et al. Allogeneic or autologous bone marrow or peripheral blood transplantation for follicular lymphoma. a cohort analysis from the Fred Hutchinson Cancer Research Center. Blood 94 (1999) 164a
11. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
12. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
13. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation. an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316
14. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
15. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 2453-2463
16. Davies A.J., Rohatiner A.Z., Howell S., et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 22 (2004) 1469-1479
17. Witzig T.E., White C.A., Gordon L.I., et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 1263-1270
18. Oki Y., Pro B., Delpassand E., et al. A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 104 (2004) 2632a
19. Morschhauser F., Huglo D., Martinelli G., et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation. results of an open-label phase II trial. Blood 104 (2004) 130a
20. Press O.W., Eary J.F., Appelbaum F.R., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329 (1993) 1219-1224
21. Gopal A.K., Rajendran J.G., Petersdorf S.H., et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99 (2002) 3158-3162
22. Gopal A.K., Gooley T.A., Maloney D.G., et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma. a multivariable cohort analysis. Blood 102 (2003) 2351-2357
23. Vose J.M., Bierman P.J., Enke C., et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 461-467
24. Winter J.N. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma 5 suppl 1 (2004) S22-S26
25. Nademanee A., Forman S., Molina A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 (2005) 2896-2902
26. Behr T.M., Griesinger F., Riggert J., et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 94 (2002) 1363-1372
27. Matthews D.C., Appelbaum F.R., Eary J.F., et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94 (1999) 1237-1247
28. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107(5) (2006) 2184-2191 Mar 1
29. Pagel J., Appelbaum F., Rajendran J., et al. 131I-anti-CD45 antibody plus fludarabine, low-dose TBI and PBSC infusion for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 106 (2005) 119a
30. Johnson T.A., and Press O.W. Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 85 (2000) 104-112
31. Pagel J.M., Hedin N., Subbiah K., et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101 (2003) 2340-2348
32. Forero A., Weiden P.L., Vose J.M., et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104 (2004) 227-236
33. Press O.W., Corcoran M., Subbiah K., et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98 (2001) 2535-2543
34. Linden O., Kurkus J., Garkavij M., et al. A novel platform for radioimmunotherapy. extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma. Cancer Biother Radiopharm 20 (2005) 457-466